Blar i Department of Clinical Science på tidsskrift "Frontiers in Oncology"
Viser treff 1-6 av 6
-
Brainstem NTCP and dose constraints for carbon ion RT—Application and translation from Japanese to European RBE-weighted dose
(Journal article; Peer reviewed, 2020)Background and Purpose: The Italian National Center of Oncological Hadrontherapy (CNAO) has applied dose constraints for carbon ion RT (CIRT) as defined by Japan’s National Institute of Radiological Sciences (NIRS). However, ... -
CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup
(Journal article; Peer reviewed, 2020-02-11)Background: Survival of metastatic colorectal cancer (mCRC) patients has improved, but mainly for trial patients. New predictive and prognostic biomarkers validated in the general mCRC population are needed. Caudal-type ... -
Colony stimulating factor 1 receptor in acute myeloid leukemia
(Journal article; Peer reviewed, 2021)Acute myeloid leukemia (AML) is an aggressive heterogeneous blood cancer derived from hematopoietic stem cells. Tumor-stromal interactions in AML are of importance for disease development and therapy resistance, and bone ... -
The Interplay Between Prostate Cancer Genomics, Metabolism, and the Epigenome: Perspectives and Future Prospects
(Journal article; Peer reviewed, 2021)Prostate cancer is a high-incidence cancer, often detected late in life. The prostate gland is an accessory gland that secretes citrate; an impaired citrate secretion reflects imbalances in the activity of enzymes in the ... -
KRAS-G12C mutation in one real-life and three population-based Nordic cohorts of metastatic colorectal cancer
(Journal article; Peer reviewed, 2022-02-16)Background: KRAS mutations, present in over 40% of metastatic colorectal cancer (mCRC), are negative predictive factors for anti-EGFR therapy. Mutations in KRAS-G12C have a cysteine residue for which drugs have been ... -
Stage-dependent prognostic shift in mismatch repair-deficient tumors: Assessing patient outcomes in stage II and III colon cancer
(Journal article; Peer reviewed, 2022)Introduction: Deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H) is associated with an improved prognosis in colon cancer stage II but poor prognosis in stage IV colon cancer. The clinical significance ...